title: Long-term effects of ranirestat (AS-3201) on peripheral nerve function in patients with diabetic sensorimotor polyneuropathy.
abstract: OBJECTIVE
  We aimed to determine whether ranirestat, an aldose reductase inhibitor, maintains the improved nerve function observed in patients with diabetic sensorimotor polyneuropathy (DSP) after completing a 12-week nerve biopsy study.
  
  
  METHODS
  Patients with mild to moderate DSP, as determined by the presence of sural nerve responses, were enrolled in a double-blind, placebo-controlled biopsy trial and randomized to placebo or 5 or 20 mg/day ranirestat for 12 weeks. Patients completing this biopsy study were offered a 48-week extension at the same ranirestat dose or at 5 mg/day ranirestat if they were originally treated with placebo. Electrophysiological tests, the Toronto Clinical Neuropathy Score, and vibration perception thresholds (VPTs) were performed at entry and at 12 (end of the biopsy study) and 60 (end of the 48-week extension) weeks.
  
  
  RESULTS
  Peroneal motor nerve conduction velocity (NCV) improved in the 20-mg/day group following 60 weeks of treatment. Sural and median sensory NCV improved after both 12 and 60 weeks of treatment with 20 mg/day. VPT improved after 60 weeks of treatment with 20 mg/day. Ranirestat was well tolerated with no difference in adverse events between the 5- and 20-mg/day groups.
  
  
  CONCLUSIONS
  Twenty milligrams ranirestat per day improves NCV and VPT following 60 weeks of administration. The improved sensory nerve function observed after 12 weeks of therapy was maintained at 60 weeks, and improved motor nerve function was observed at 60 weeks.
authors.affiliation: Department of Medicine, University of Toronto, Canada. vera.bril@utoronto.ca
authors.forename: Vera
authors.initials: V
authors.lastname: Bril
authors.forename: Robert A
authors.initials: RA
authors.lastname: Buchanan
mesh_terms: D000449:Aldehyde Reductase / Q000037:antagonists & inhibitors; D001786:Blood Glucose / Q000378:metabolism; D003922:Diabetes Mellitus, Type 1 / Q000503:physiopathology; D003924:Diabetes Mellitus, Type 2 / Q000503:physiopathology; D003929:Diabetic Neuropathies / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology*; D004311:Double-Blind Method; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D006442:Glycated Hemoglobin / Q000032:analysis; D006801:Humans; D009046:Motor Neurons / Q000502:physiology; D009431:Neural Conduction / Q000502:physiology; D018579:Patient Selection; D010525:Peripheral Nerves / Q000187:drug effects / Q000503:physiopathology*; D010543:Peroneal Nerve / Q000503:physiopathology*; D010919:Placebos; D011719:Pyrazines / Q000627:therapeutic use*; D013141:Spiro Compounds / Q000627:therapeutic use*; D013497:Sural Nerve / Q000503:physiopathology
chemical_list: D000449:Aldehyde Reductase; D001786:Blood Glucose; D004791:Enzyme Inhibitors; D006442:Glycated Hemoglobin; D010919:Placebos; D011719:Pyrazines; D013141:Spiro Compounds; C115070:ranirestat